Novartis's multiple sclerosis treatment remibrutinib cut relapse rates by a third compared with a standard treatment in pivotal trials, STAT reports. STAT
STATNovartis multiple sclerosis treatment cuts rates of relapse in pivotal trialsAn MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment.
How much does a one-third reduction in relapses matter to patients compared with existing options?
